FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy

Lonza steps up for GSK and Genmab

Arzerra, the recently approved monoclonal antibody treatment for leukemia from GlaxoSmithKline and Genmab, will be manufactured by Lonza. The Swiss-based contract manufacturer performed process development and cGMP manufacturing services to support the drug's licensure.

According to Lonza, Arzerra treats chronic lymphocytic leukemia by alerting the immune system to protect B-cells, which become cancerous as a result of the disease. The drug attaches to epitope molecules on the cells' surface.

Separately, Lonza has acquired AlgoNomics NV, a Belgium-based provider of immunogenicity screening services and tools. The AlgoNomics Tripole technology platform supports Lonza's aim to incorporate quality by design at the molecular level, improving the manufacturability of protein-based drugs. 

- here's the Arzerra announcement
- read the AlgoNomics release

Related Article:
Lonza Group Buys AlgoNomics


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:
Be the first to comment
More stories about Contract Manufacturer   Glaxosmithkline   Monoclonal Antibody   Manufacturability   Genmab   Lonza  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.